Relationship between Plasma Neuregulin-1 and MDA Levels with Severity of CAD

Gestina Aliska; Muhammad Fadil; Yose Ramda Ilhami; Elly Usman; Ivan Mahendra Raditya; Rahma Tsania Zhuhra; Robby Alfadli

doi:10.3889/oamjms.2020.4520

Authors

Gestina Aliska Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas, Indonesia
Muhammad Fadil Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Andalas, Indonesia
Yose Ramda Ilhami Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Andalas, Indonesia
Elly Usman Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Andalas
Ivan Mahendra Raditya Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Andalas, Indonesia
Rahma Tsania Zhuhra Department of Medical Education, Faculty of Medicine, Universitas Andalas, Indonesia
Robby Alfadli Undergraduate Program, Faculty of Medicine, Universitas Andalas, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.4520

Keywords:

malondialdehyde, cardiac injury, coronary arterial disease, severity of CAD, Neuregulin-1

Abstract

BACKGROUND: Neuregulins (NRGs) are one of the epidermal growth factors (EGF) superfamily, which released in cellular injuries, such as neurons and myocardial cells. Neuregulin-1β (NRG-1β) could be activated when stress happens to myocardial cells, acting as a survival factor to repair the injury. Malondialdehyde (MDA) is also produced during oxidative stress in cardiac injury. In vivo study of myocardial cells in rats and dogs that got ischemic, dilated, and viral cardiomyopathy showed that NRG-1 could improve the injured cardiac performance, attenuated pathological changes, and prolonged survival of the cells.

AIM: We aimed to observe NRG-1 levels in CAD patients in Indonesia, mainly focused in Minang ethnicity. This study also analyzes the relationship between NRG-1 and MDA with CAD’s severity.

METHODS: We measured plasma NRG-1 in 61 nondiabetic patients within 38–82 years old range with STEMI, NSTEMI, and UAP.

RESULTS: We found their plasma NRG1, respectively, was 10.3 (1.9–38.2) ng/ml, 14.3 ± 7.2 ng/ml, and 7.05 (4.5–0.4) ng/mL. Plasma NRG 1 increased in AMI patients.

CONCLUSION: This study concludes that NRG1’s activated during cardiac cells injury, in any AMI.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Xiao J, Li B, Zheng Z, Wang M, Peng J, Li Y, et al. Therapeutic effects of neuregulin-1 gene transduction in rats with myocardial infarction. Coron Artery Dis. 2012;23(7):460-8. https://doi. org/10.1097/mca.0b013e32835877da PMid:22968213

Geisberg CA, Wang G, Safa RN, Smith HM, Anderson B, Peng XY, et al. Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron Artery Dis. 2011;22(8):577-82. https://doi. org/10.1097/mca.0b013e32834d3346 PMid:22027878

Huang M, Zheng J, Chen Z, You C, Huang Q. The relationship between circulating neuregulin-1 coronary collateral circulation in patients with coronary artery disease. Int Heart J. 2020;61(1):115-20. https://doi.org/10.1536/ihj.19-277 PMid:31956140

Khaki-Khatibi F, Yaghoubi AR, Rahbani NM. Study of antioxidant enzymes, lipid peroxidation, lipid profile and immunologic factor in coronary artery disease in East Azarbijan. Int J Med Biomed Res. 2013;1(2):147-52. https://doi.org/10.14194/ijmbr.1210

Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, et al. Neuregulin-1 beta is associated with disease severity and adverse outcomes in chronic heart failure. Circulation. 2009;120(4):310- 7. https://doi.org/10.1161/circulationaha.109.856310 PMid:19597049

Goldshmit Y, Erlich S, Pinkas-Kramarski R. Neuregulin rescues PC12-ErbB4 cells from cell death induced by H(2) O(2). Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J Biol Chem. 2001;276(49):46379- 85. https://doi.org/10.1074/jbc.m105637200 PMid:11590144

Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, et al. SYNTAX score and long-term outcomes: The BARI-2D trial. J Am Coll Cardiol. 2017;69(4):395-403. PMid:28126156

Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, Liao R, et al. Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/ erbB4 signaling. J Biol Chem. 2004;279(49):51141-7. https:// doi.org/10.1074/jbc.m408662200 PMid:15385548

Cai WF, Liu GS, Wang L, Paul C, Wen ZL, Wang Y. Repair injured heart by regulating cardiac regenerative signals. Stem Cells Int. 2016;2016:6193419. https://doi.org/10.1155/2016/6193419 PMid:27799944

Rupert CE, Coulombe KL. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights. 2015;10(Suppl 1):1-9. https://doi.org/10.4137/bmi.s20061 PMid:25922571

Dunn SP, Kazmi H. Antithrombotic therapies in acute coronary syndrome. In: CCSAP Cardiology Critical Care. Lenexa, KS: American College of Clinical Pharmacy; 2017. p. 1-34.

Widmer RJ, Lerman A. Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract. 2014;2014(3):291-308. PMid:25780786

Yoder MC. Human endothelial progenitor cells. Cold Spring Harb Perspect Med. 2011;2(7):a006692. https://doi.org/10.1101/ cshperspect.a006692 PMid:22762017

Van Belle E, Bauters C, Asahara T, Isner JM. Endothelial regrowth after arterial injury: From vascular repair to therapeutics. Cardiovasc Res. 1998;38(1):54-68. https://doi. org/10.1016/s0008-6363(97)00326-x PMid:9683907

Mao RM, Du ZB, Gao WM, Mi L, Zhu BL. Time-dependent expression of vascular endothelial growth factor after acute myocardial ischemia in rats. Fa Yi Xue Za Zhi. 2012;28:179-84. PMid:22812217

Wang Z, Si LY. Hypoxia-inducible factor-1α and vascular endothelial growth factor in the cardioprotective effects of intermittent hypoxia in rats. Ups J Med Sci. 2013;118(2):65-74. https://doi.org/10.3109/03009734.2013.766914 PMid:23441597

Orlandi A, Bennett M. Progenitor cell-derived smooth muscle cells in vascular disease. Biochem Pharmacol. 2010;79:1706- 13. https://doi.org/10.1016/j.bcp.2010.01.027 PMid:20117099

Niu J, Han X, Qi H, Yin J, Zhang Z. Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial infarction. Exp Ther Med. 2016;12(1):475- 9. https://doi.org/10.3892/etm.2016.3286 PMid:27347081

Wu C, Gui C, Li L, Pang Y, Tang Z, Wei J. Expression and secretion of neuregulin-1 in cardiac microvascular endothelial cells treated with angiogenic factors. Exp Ther Med. 2018;15(4):3577-81. https://doi.org/10.3892/etm.2018.5811 PMid:29545886

Zeng Z, Gui C, Nong Q, Du F, Zhu L. Serum neuregulin-1β levels are positively correlated with VEGF and angiopoietin-1 levels in patients with diabetes and unstable angina pectoris. Int J Cardiol. 2013;3077-9. https://doi.org/10.1016/j.ijcard.2013.04.088 PMid:23642614

Kang W, Cheng Y, Zhou F, Wang L, Zhong L, Li H, et al. Neuregulin-1 protects cardiac function in septic rats through multiple targets based on endothelial cells. Int J Mol Med. 2019;44(4):1255-66. https://doi.org/10.3892/ijmm.2019.4309 PMid:31432099

Tajika K, Okamatsu K, Takano M, Inami S, Yamamoto M, Murakami D, et al. Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque. Circ J. 2012;76:2211-7. https://doi.org/10.1253/circj. cj-12-0183 PMid:22785057

Venkata R, Ravi K. Evaluation of correlation between oxidative stress and abnormal lipid profile in coronary artery disease. J Cardiovasc Dis Res. 2011;2(1):57-60. PMid:21716754

Matsuo Y, Kubo T, Okumoto Y, Ishibashi K, Komukai K, Tanimoto T, et al. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. Eur Heart J Cardiovasc Imaging. 2013;14:43-50. https://doi.org/10.1093/ehjci/jes094 PMid:22573905

Abolhasani A, Shahbazloo SV, Saadati HM, Mahmoodi N, Khanbabaei N. Evaluation of serum levels of inflammation, fibrinolysis and oxidative stress markers in coronary artery disease prediction: A cross-sectional study. Arq Bras Cardiol. 2019;113(4):667-74. https://doi.org/10.5935/ abc.20190159 PMid:31691749

Jung HH, Choi DH, Lee SH. Serum malondialdehyde and coronary artery disease in hemodialysis patients. Am J Nephrol. 2004;24:537-42. https://doi.org/10.1159/000081731 PMid:15523169

Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Cardiol. 2019;74:258-66. https://doi. org/10.1016/j.jjcc.2019.02.012 PMid:30898480

Wu T, Rifai N, Roberts LJ. Stability of Measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiol Biomarkers Prev. 2004;13(8):1399-402 PMid:15298964

Khan MA, Baseer A. Increased malondialdehyde levels in coronary heart disease. J Pak Med Assoc. 2000;50(8):261-4. PMid:10992710

Cheraghi M, Ahmadvand H, Maleki A, Babaeenezhad E, Shakiba S, Hassanzadeh F. Oxidative stress status and liver markers in coronary heart disease. Rep Biochem Mol Biol. 2019;8(1):49-55. PMid:31334288

Bermudez V, Acosta L, Aparicio D, Finol F, Canelon R, Urdaneta A, et al. Smoking habits and cardiovascular disease. Rev Latinoam Hipertens. 2010;5:19-27.

Roy A, Rawal I, Jabbour S, Prabhakaran D. Tobacco and cardiovascular disease: A summary of evidence. In: Prabhakaran D, Anand S, Gaziano TA, Watkins DA, Wu Y, Mbanya JC, et al., editors. Cardiovascular, Respiratory, and Related Disorders. 3rd ed., Ch. 4. Washington, DC: The International Bank for Reconstruction and Development, The World Bank; 2017. https://doi.org/10.1596/978-1-4648-0518-9_ch4